PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biopharmaceutical company focused on developing autologous cell-based therapies for chronic kidney disease. The company entered public markets through a SPAC business combination in 2022, operating within the biotechnology and life sciences sector. Its 8-K filing dated July 12, 2022 represents an early regulatory disclosure submitted to the SEC shortly after the company's listing as a newly public entity. ProKidney's therapeutic platform is designed to preserve or restore kidney function using a patient's own cells, targeting a large and chronically underserved patient population. The company continues to operate as a clinical-stage entity advancing its development pipeline. Sign up at SpacDesk for full data on ProKidney Corp. and hundreds of other SPAC transactions.